Christof Bull
Associate General Patent Counsel
UCB Biopharma
Personal Profile
Christof Bull is a European Patent Attorney and Associate General Patent Counsel for UCB, a global biopharmaceutical company headquartered in Brussels, Belgium.
Christof has been working as in-house patent counsel for several biopharma companies for more than 19 years. He joined UCB in 2008. Prior to UCB, Christof worked at Merck Serono and Serono in Geneva, Switzerland and at Bayer AG in Leverkusen, Germany.
Christof has also spent more than one year working for UCB’s China affiliate in Shanghai in 2018 and 2019.
At UCB Christof heads up a team of biotech patent attorneys supporting globally biotechnology products as well as biotech manufacturing activities with respect to all IP matters. Christof has extensive experience with all key aspects of intellectual property. During the many years as in-house patent counsel, Christof has gained substantial experience in patent prosecution, particularly in the field of antibodies and other biologicals, has been handling contentious matters such as opposition, appeals and patent litigation. He has been involved in numerous negotiations related to transactions and handled IP due diligences, including with respect to monoclonal antibody products, as well as technologies for antibody discovery and biotech manufacturing. Lately, Christof has spent a lot of time with IP management, strategy, policy and advocacy.
Christof, who is a German national, studied biochemistry in Berlin, Germany and received his Ph.D. in molecular immunology from the Freie Universität Berlin in 1999. He has subsequently worked in human genetics as a post-doctoral scientist at the Max-Planck-Institute for Molecular Genetics.
UCB (www.ucb.com) has a strong footprint in epilepsy and other CNS diseases as well as autoimmune diseases. Through the acquisition of the British biotech pioneer Celltech in 2004, UCB acquired cutting-edge antibody discovery capabilities and a strong biotech pipeline with the anti-TNF Cimzia® which was launched in 2008 as UCB’s first innovative biotech product. Evenity®, a monoclonal antibody for the treatment of osteoporosis which UCB jointly develops with Amgen, recently obtained approval in the US and Japan. UCB has various antibody products in different stages of clinical development.
Christof has been working as in-house patent counsel for several biopharma companies for more than 19 years. He joined UCB in 2008. Prior to UCB, Christof worked at Merck Serono and Serono in Geneva, Switzerland and at Bayer AG in Leverkusen, Germany.
Christof has also spent more than one year working for UCB’s China affiliate in Shanghai in 2018 and 2019.
At UCB Christof heads up a team of biotech patent attorneys supporting globally biotechnology products as well as biotech manufacturing activities with respect to all IP matters. Christof has extensive experience with all key aspects of intellectual property. During the many years as in-house patent counsel, Christof has gained substantial experience in patent prosecution, particularly in the field of antibodies and other biologicals, has been handling contentious matters such as opposition, appeals and patent litigation. He has been involved in numerous negotiations related to transactions and handled IP due diligences, including with respect to monoclonal antibody products, as well as technologies for antibody discovery and biotech manufacturing. Lately, Christof has spent a lot of time with IP management, strategy, policy and advocacy.
Christof, who is a German national, studied biochemistry in Berlin, Germany and received his Ph.D. in molecular immunology from the Freie Universität Berlin in 1999. He has subsequently worked in human genetics as a post-doctoral scientist at the Max-Planck-Institute for Molecular Genetics.
UCB (www.ucb.com) has a strong footprint in epilepsy and other CNS diseases as well as autoimmune diseases. Through the acquisition of the British biotech pioneer Celltech in 2004, UCB acquired cutting-edge antibody discovery capabilities and a strong biotech pipeline with the anti-TNF Cimzia® which was launched in 2008 as UCB’s first innovative biotech product. Evenity®, a monoclonal antibody for the treatment of osteoporosis which UCB jointly develops with Amgen, recently obtained approval in the US and Japan. UCB has various antibody products in different stages of clinical development.
